In this study, those findings were reproduced using a 3rd lung cancer model that is wild-type to both EGFR and KRAS oncogenes, thereby confirming the wider efficacy of inhaled topotecan against tumors that vary based on the two most common cancer-driver oncogenes in lung cancer. The gene discussed is EGFR; the disease is lung cancer.